|
| Press Releases |
|
 |
|
| Monday, October 17, 2022 |
|
|
The Biotech Landscape Webinar: Market Trends, Priorities, Predictions, and Pathways to FDA Approval |
| Novotech, the leading Asia Pacific biotech specialist CRO, and Endpoints News present a webinar for biotechs considering the clinical research opportunities in Asia Pacific and the regulatory pathways to achieving FDA approval. more info >> |
|
| Wednesday, October 12, 2022 |
|
|
Novotech India Recognised as "Best Workplaces for Women 2022" by Global Work Standards Authority |
| Novotech, the leading Asia Pacific biotech specialist CRO, has again received "Best Workplace" certification by the leading workplace culture organization Great Place to Work Institute. Novotech's India team has received a Best Workplaces for Women 2022 recognition and listed in the Top 75 organisations in India recognised for excelling people practices, responsiveness to feedback and a culture of openness and diversity. more info >> |
|
| Friday, October 7, 2022 |
|
|
Novotech Selected as Scrip Awards Finalist for Best Full-Service CRO |
| Novotech, the leading Asia Pacific biotech specialist CRO, joins a prestigious group of global CROs as a finalist in the Scrip Award for Best Full-Service CRO. This year the Award has been split into two categories to separate the full-service providers from the smaller CROs. more info >> |
|
| Thursday, September 15, 2022 |
|
|
Novotech presented with Cell & Gene Excellence Award 2022 at 6th Cell & Gene Therapy World Asia Conference |
| Novotech, the leading Asia Pacific biotech specialist CRO, has been awarded the Cell & Gene Therapy Clinical Trials award at the 6th Cell & Gene Therapy World Asia 2022 conference. more info >> |
|
| Monday, September 5, 2022 |
|
|
Novotech at ESMO Congress 2022 - New Data Shows 100% Oncology Trials Growth in APAC |
| Novotech, the leading Asia Pacific biotech specialist CRO, will attend ESMO Congress 2022 with new data showing Asia Pacific has seen a 100% growth in oncology trials during 2017 to 2021 and contributes to more than a third of the global clinical development of immune-oncology drugs. more info >> |
|
| Friday, September 2, 2022 |
|
|
APAC Attracts 50% of Global Clinical Trials According to New GlobalData Report |
| Novotech, the leading Asia Pacific biotech specialist CRO has released new market data in a report now available titled "Evolution of Clinical Trials in the Asia Pacific Region". The report was prepared by GlobalData and confirms that "the Asia-Pacific (APAC) region was the largest contributor to the global clinical trial landscape from 2017 to 2021, accounting for more than 50% of conducted trials during the analysis period." more info >> |
|
| Monday, July 25, 2022 |
|
|
Novotech's Flexible Work Policy is Finalist in Best Workplace Flexibility Program "Excellence Award 2022" |
| Novotech, the leading Asia Pacific biotech specialist CRO with expanded services in the US, has been recognised for its innovative approach to workplace flexibility. more info >> |
|
| Monday, July 18, 2022 |
|
|
Novotech and Endpoints Present "Evolution of Cell & Gene Therapy in China: The Case for Universal CAR-T" |
| Novotech, the leading Asia Pacific biotech specialist CRO with expanded services in the US, is pleased to present an Endpoints webinar on CAR-T therapy in China - the current landscape and future opportunities. more info >> |
|
| Wednesday, July 13, 2022 |
|
|
Novotech Client SK bioscience Achieves SKYCovione(TM) COVID-19 Vaccine Approval in Korea |
| Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, congratulates its client SK bioscience on the recent COVID-19 vaccine licence approval. more info >> |
|
| Wednesday, June 29, 2022 |
|
|
Novotech Receives "Best Biologics CRO Award 2022" at Korea Bioprocessing Excellence Awards 2022 |
| Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, was today awarded the Best Biologics CRO Award at a ceremony as part of 11th Biologics Manufacturing Korea, the 6th Cell & Gene Therapy World East Asia, and the 3rd BioLogistics World Korea conferences (29th - 30th June 2022) which attract more than 300 representatives from Korea's top biopharmas, vaccine manufacturers, and biologics companies. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
APEL Products Shine on the World Stage:Redefining Health and Sustainability - A Roadmap to Transformative Impact 
Mar 10, 2025 21:22 HKT/SGT
|
|
|
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time
Mar 10, 2025 20:24 JST
|
|
|
Entertainment Expo makes grand return
Mar 10, 2025 19:08 HKT/SGT
|
|
|
Hong Kong products highly rated by ASEAN e-shoppers
Mar 10, 2025 18:35 HKT/SGT
|
|
|
The New Economics of Power Markets in a Low-Carbon World 2025
Mar 10, 2025 18:20 HKT/SGT
|
|
|
CITIC Telecom CPC Wins Outstanding Award at 2025 Hong Kong Sustainable Development Innovation and Technology Awards
Mar 10, 2025 17:44 HKT/SGT
|
|
|
Big Ideas, Bold Leaders: Big CIO Show and Awards is Where Business Meets Innovation
Mar 10, 2025 16:41 HKT/SGT
|
|
|
DX Leaders Philippines 2025: Accelerating IT Innovation in a $40B Digital Economy
Mar 10, 2025 15:34 HKT/SGT
|
|
|
The PropertyGuru Asia Awards Malaysia in Partnership with iProperty return with 23 new categories in 2025
Mar 10, 2025 14:00 HKT/SGT
|
|
|
World's Most Sleep-Deprived Nation Has a Gender Crisis: Why Singaporean Women Bear the Heaviest Burden
Mar 10, 2025 13:00 HKT/SGT
|
|
|
uSMART Securities Surges 300% in Hong Kong Local Users
Mar 10, 2025 12:28 HKT/SGT
|
|
|
Hola Prime to Introduce Prime Academy for Personalized Trader Mentorship
Mar 10, 2025 12:00 HKT/SGT
|
|
|
CEPI funds Nagasaki University to develop innovative vaccines using Nanoball platform and NEC's AI
Mar 10, 2025 12:10 JST
|
|
|
Twin jewellery shows attract over 82,000 global buyers
Mar 9, 2025 13:19 HKT/SGT
|
|
|
uSMART Securities Initiates Coverage on NAAS Technology with a 'Buy' Rating and a Target Price of US$3.2 per ADS, Citing Industry Leadership and Profitability Outlook
Mar 7, 2025 20:26 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
